ALUR vs. TLSI, DRTS, ELMD, FONR, VANI, PDEX, SURG, SEPA, STIM, and CTSO
Should you be buying Allurion Technologies stock or one of its competitors? The main competitors of Allurion Technologies include TriSalus Life Sciences (TLSI), Alpha Tau Medical (DRTS), Electromed (ELMD), FONAR (FONR), Vivani Medical (VANI), Pro-Dex (PDEX), SurgePays (SURG), SEP Acquisition (SEPA), Neuronetics (STIM), and Cytosorbents (CTSO). These companies are all part of the "medical equipment" industry.
TriSalus Life Sciences (NASDAQ:TLSI) and Allurion Technologies (NYSE:ALUR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, community ranking, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.
TriSalus Life Sciences has higher earnings, but lower revenue than Allurion Technologies.
TriSalus Life Sciences has a net margin of 0.00% compared to TriSalus Life Sciences' net margin of -117.30%.
TriSalus Life Sciences has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500. Comparatively, Allurion Technologies has a beta of -0.3, indicating that its share price is 130% less volatile than the S&P 500.
TriSalus Life Sciences received 1 more outperform votes than Allurion Technologies when rated by MarketBeat users.
In the previous week, Allurion Technologies had 1 more articles in the media than TriSalus Life Sciences. MarketBeat recorded 3 mentions for Allurion Technologies and 2 mentions for TriSalus Life Sciences. Allurion Technologies' average media sentiment score of 1.43 beat TriSalus Life Sciences' score of 0.33 indicating that TriSalus Life Sciences is being referred to more favorably in the media.
TriSalus Life Sciences currently has a consensus price target of $13.33, suggesting a potential upside of 133.92%. Allurion Technologies has a consensus price target of $5.00, suggesting a potential upside of 482.07%. Given TriSalus Life Sciences' higher possible upside, analysts plainly believe Allurion Technologies is more favorable than TriSalus Life Sciences.
2.6% of TriSalus Life Sciences shares are owned by institutional investors. Comparatively, 21.4% of Allurion Technologies shares are owned by institutional investors. 76.2% of TriSalus Life Sciences shares are owned by company insiders. Comparatively, 20.0% of Allurion Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
TriSalus Life Sciences beats Allurion Technologies on 8 of the 13 factors compared between the two stocks.
Get Allurion Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALUR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Allurion Technologies Competitors List
Related Companies and Tools
Free ALUR Stock Alerts